November/December 2013 Newsletter

ASBM Releases New European Survey in Dublin On November 22, ASBM Executive Director Michael Reilly presented preliminary findings of a new survey on European physicians’ views on biosimilar naming at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety: 53% of physicians surveyed […]

Read More


October 2013 Newsletter

FTC to Host Workshop on Biosimilars The Federal Trade Commission (FTC) will be holding a public workshop on December 10, 2013 in D.C. to discuss competition issues surrounding biologics and biosimilars. The workshop will specifically focus on how state regulations and naming conventions may impact the development of, and competition for, biosimilars. The FTC will […]

Read More


September 2013 Newsletter

Dolinar Letter to the Editor Published by GaBI in Advance of WHO Naming Meeting On September 27th, a Letter to the Editor by ASBM Chairman Richard Dolinar, M.D. was featured in the Generics and Biosimilars Initiative Journal (GaBI). The piece commends the World Health Organization (WHO) for its attention to an upcoming action on the […]

Read More


July – August / Summer 2013 Newsletter

Dolinar Authors Second Letter to WHO on Naming ASBM Chairman Richard Dolinar, M.D., submitted a letter on July 31, 2013, to Dr. Margaret Chan, World Health Organization Director-General to reiterate ASBM’s position on the importance of using distinct non-proprietary names to ensure patient safety. The letter was sent to Dr. Chan and to the INN […]

Read More


June 2013 Newsletter

Inside Health Policy: “Safety, Generic Concerns Factors in Proposed AMA Biosimilar Resolution” A perceived lack of safety information about biosimilars and past problems with substitution of generic drugs led neurologists and rheumatologists to ask the American Medical Association to study the safety of follow-on biologics. AMA is expected to considerer the topic further at a […]

Read More


May 2013 Newsletter

State Legislation Update Several state legislatures have have adjourned for the year, but we continue to urge support for California Senate Bill 598, which passed off the Senate Floor (29-4) on Friday, May 24. The bill now heads to the State Assembly where it is expected to be double-referred to the Assembly Business, Professions and […]

Read More


April 2013 Newsletter

State Legislation Update ASBM member organizations and our Advisory Board members have been actively supporting patient-focused legislation on biosimilar substitution by sending letters and testifying at hearings, particularly in California, Colorado, Florida, Indiana and Maryland. In California, SB 598, which we support, passed out of the Senate Business, Professions and Economic Development Committee hearing on […]

Read More


March 2013 Newsletter

State Activity More than 15 state legislatures have introduced legislation on substitution over the past few months and ASBM and our members have been very active sending letters of support, testifying at hearings and briefing state legislators on the issue of interchangeability and the need for physician notification. Virginia and North Dakota have both signed […]

Read More


February 2013 Newsletter

State Activity With the start of a new year, comes the start of a new legislative calendar. The past weeks have been very busy as many states are considering substitution legislation. ASBM and our members have been sending in letters of support in CO, VA, IN and ND and will continue to express our concerns […]

Read More


January 2013 Newsletter

ASBM Shows Support for VA Legislation on Interchangeability The Virginia House of Delegates introduced legislation on interchangeable biosimilars and held a hearing on the bill, H.B.1422, on January 15. To show support of the bill, Dr. Dolinar, the Colon Cancer Alliance, Global Healthy Living Foundation and the Kidney Cancer Association sent letters to members of […]

Read More